Atle Fund Management AB Has $9.43 Million Stake in Stryker Corporation $SYK

Atle Fund Management AB grew its position in Stryker Corporation (NYSE:SYK) by 17.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,835 shares of the medical technology company’s stock after purchasing an additional 4,066 shares during the quarter. Stryker comprises approximately 3.0% of Atle Fund Management AB’s investment portfolio, making the stock its 11th biggest position. Atle Fund Management AB’s holdings in Stryker were worth $9,432,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in SYK. Brighton Jones LLC grew its position in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares in the last quarter. Schnieders Capital Management LLC. acquired a new stake in shares of Stryker in the 2nd quarter valued at $205,000. Marshall Wace LLP boosted its holdings in shares of Stryker by 107.9% in the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after purchasing an additional 77,831 shares in the last quarter. Nebula Research & Development LLC acquired a new stake in shares of Stryker in the 2nd quarter valued at $219,000. Finally, HUB Investment Partners LLC acquired a new stake in shares of Stryker in the 2nd quarter valued at $253,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

Shares of NYSE SYK opened at $317.81 on Wednesday. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The stock has a market cap of $121.84 billion, a price-to-earnings ratio of 36.78, a PEG ratio of 1.97 and a beta of 0.80. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The firm’s 50-day simple moving average is $327.61 and its 200 day simple moving average is $350.70.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same period in the previous year, the business posted $2.84 EPS. Stryker’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, research analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is currently 40.74%.

Analyst Ratings Changes

A number of research analysts have recently commented on SYK shares. The Goldman Sachs Group reiterated a “neutral” rating and issued a $361.00 price target on shares of Stryker in a research note on Friday, May 1st. William Blair reiterated an “outperform” rating on shares of Stryker in a research note on Thursday, March 5th. Wells Fargo & Company decreased their price objective on Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. UBS Group decreased their price objective on Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a report on Tuesday, March 17th. Finally, Truist Financial restated a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Sixteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $395.48.

Insider Activity at Stryker

In other news, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president directly owned 13,137 shares in the company, valued at $3,728,937.45. The trade was a 28.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.60% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.